Phase III trial of ublituximab in combination with TGR 1202 in patients with indolent non-Hodgkin's lymphoma

Trial Profile

Phase III trial of ublituximab in combination with TGR 1202 in patients with indolent non-Hodgkin's lymphoma

Planning
Phase of Trial: Phase III

Latest Information Update: 15 Jun 2017

At a glance

  • Drugs Ublituximab (Primary) ; Umbralisib (Primary)
  • Indications Non-Hodgkin's lymphoma
  • Focus Registrational; Therapeutic Use
  • Acronyms UNITY-iNHL
  • Most Recent Events

    • 15 Jun 2017 According to TG Therapeutics media release, the company is planning to add Triple Combination of TG-1101, TGR-1202, and Bendamustine in DLBCL arm in UNITY-NHL program and enroll patients into this cohort before the end of the summer 2017.
    • 10 May 2016 The company is planning to initiate this trial before end of the year 2016, as reported in a TG Therapeutics media release.
    • 19 Jan 2016 Planned initiation date changed from 1 Jul 2015 to 1 Jul 2016, as per a TG Therapeutics Inc media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top